Vertex Pharma (VRTX) ebitda was $5.1B in FY2025 (+653% YoY). The tables below show the complete quarterly and annual ebitda history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual EBITDA
Fiscal Year
EBITDA
YoY
2025
$5.1B
+653%
2024
$673M
-85%
2023
$4.6B
-7%
2022
$4.9B
+48%
2021
$3.3B
-1%
2020
$3.4B
+104%
2019
$1.7B
+61%
2018
$1.0B
+110%
2017
$492M
+57%
2016
$313M
+283%
2015
-$171M
+57%
2014
-$401M
-2%
2013
-$394M
-297%
2012
$201M
-25%
2011
$269M
+147%
2010
-$573M
-17%
2009
-$491M
-33%
2008
-$368M
Recent Quarterly EBITDA
Quarter
EBITDA
Q1 2026
$1.4B
Q4 2025
$1.4B
Q3 2025
$1.4B
Q2 2025
$1.4B
Q1 2025
$845M
Q4 2024
$1.2B
Q3 2024
$1.4B
Q2 2024
-$3.3B
Q1 2024
$1.4B
Q4 2023
$1.3B
Q3 2023
$1.2B
Q2 2023
$1.2B
Source: VRTX on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.